The BRICS Imperative: A Complete Guide to Generic Drug Filing Requirements for Manufacturers

The Shifting Tectonic Plates: A Macro View of the BRICS Generic Market

Before we dive into the granular details of filing requirements, it’s essential to understand the sheer scale and velocity of the market shift we are witnessing. The move towards the BRICS nations is not a fleeting trend but a long-term, structural realignment of global health demand, fueled by a powerful confluence of economic, demographic, and policy-driven forces. For any generic drug manufacturer, ignoring this shift is not just a missed opportunity; it’s a strategic blunder.

The Scale of the Opportunity: Market Size and Growth Projections

The numbers tell an unambiguous story. The global generic drugs market is on a powerful and sustained growth trajectory, projected to expand from approximately $468.08 billion in 2025 to a staggering $728.64 billion by 2034, representing a compound annual growth rate (CAGR) of 5.04%. But this growth is not evenly distributed. The most explosive expansion is happening within the BRICS bloc.

The combined BRIC generics market (Brazil, Russia, India, China) was valued at an immense $168.5 billion in 2023. China stands as the undisputed giant, with a market value of $121 billion, followed by the volume-driven Indian market at $22.8 billion, a rapidly localizing Russian market at $15.4 billion, and a high-potential Brazilian market at $9.2 billion. The forecast for 2028 is even more compelling: China is expected to surge to $177.2 billion, India to $31.5 billion, and Brazil to $14.4 billion. To put this in perspective, Brazil’s total pharmaceutical market is projected to hit nearly $49 billion by 2030, while Russia’s is expected to reach $25 billion by 2025.¹ India’s generic market alone is forecasted to cross $35 billion by 2030.

This growth isn’t just large; it’s fast. Between 2017 and 2022, the pharmaceutical markets in Brazil and India surged by 13.0% and 11.0%, respectively. During that same period, the top five European Union markets grew by an average of just 6.6%, and the US market expanded by a mere 7.1%. This “Pharma-to-GDP Growth Ratio,” where pharmaceutical market growth significantly outpaces GDP growth, signifies a fundamental shift in consumer and government spending priorities in these regions.

However, a strategic leader must look beyond these aggregate numbers. The growth narrative is not uniform across the bloc. China’s massive value is increasingly shaped by state-controlled mechanisms like the Volume-Based Procurement (VBP) program, which drives prices down to razor-thin margins. India’s growth is propelled by its unparalleled manufacturing volume and its role as a global export hub. Brazil’s expansion is fueled by its universal healthcare system (Sistema Único de Saúde or SUS) and a rising middle class with greater purchasing power. Meanwhile, Russia’s market shows robust growth in its local currency but appears flat in US dollar terms, a clear signal of a market driven by a state-led push for localization and import substitution in response to geopolitical pressures and currency devaluation.⁹ This divergence means that a “one-size-fits-all” BRICS strategy is destined for failure. Your market entry decisions must weigh not just the top-line CAGR, but the

quality and sustainability of that growth, which is inextricably linked to the unique policy environment of each nation.

The Twin Engines of Growth: Patent Cliffs and Policy Tailwinds

What is fueling this explosive expansion? The growth is powered by two interconnected engines: a massive wave of patent expiries in mature markets and a deliberate policy push within the BRICS nations to embrace generics as a cornerstone of public health.

First, the “patent cliff” is creating a historic transfer of market value. Between 2025 and 2030 alone, branded drugs generating over $200 billion in annual sales are set to lose their market exclusivity.¹ Major blockbusters like Xarelto, Entresto, and Stelara are facing loss of exclusivity, creating a steady and lucrative pipeline of opportunities for generic manufacturers to produce bioequivalent replicas at significantly lower costs.¹

Second, this supply of new generic opportunities is meeting a surge in demand driven by powerful internal forces within the BRICS nations. With a combined 40% of the world’s population, these countries represent a vast and largely untapped consumer base.¹ This demographic scale is coupled with rising prosperity, an expanding middle class, and aging populations, all of which translate into greater affordability and demand for healthcare.¹² Furthermore, the burden of healthcare costs in these regions is often staggering. In India, for example, out-of-pocket (OOP) payments account for a massive 65.6% of total healthcare expenditure, compared to just 12% in developed markets. This makes the availability of affordable generic medicines—which can cost up to 80-85% less than their branded counterparts—a public health necessity, not just a consumer choice.¹²

This creates a fascinating dynamic where two seemingly contradictory forces are at play. On one hand, BRICS governments are aggressively pushing for cheaper drugs through generic promotion, price controls, and centralized procurement to contain spiraling healthcare costs.² On the other hand, their regulatory agencies are simultaneously implementing stricter and more sophisticated quality standards, such as China’s Generic Quality Consistency Evaluation (GQCE), which significantly increase the cost and complexity of generic development and approval.¹⁵

This creates a strategic pincer movement for manufacturers. The winners in the new BRICS landscape will not be the companies that can simply produce the cheapest drugs, but those that can most efficiently produce high-quality medicines. The era of low-cost, low-quality generics dominating these markets is rapidly coming to an end. This trend fundamentally favors larger, more technologically advanced generic companies that have the capital to invest in the R&D and manufacturing excellence required to meet these new, higher standards, while also operating at a scale that allows them to remain price-competitive in government tenders.

The Regulatory Maze: A Comparative Framework for Generic Approval in BRICS

Successfully capitalizing on the BRICS opportunity requires a deep and granular understanding of five distinct regulatory systems. While there are areas of convergence, particularly around the adoption of international standards, the differences in process, philosophy, and enforcement are profound. Let’s begin by introducing the key players and establishing a comparative framework.

The Gatekeepers: Introducing the BRICS Regulatory Authorities

Each BRICS nation has a primary national regulatory body responsible for ensuring the safety, efficacy, and quality of pharmaceutical products. These are the gatekeepers you must satisfy to gain market access.

Brazil: The Agência Nacional de Vigilância Sanitária (ANVISA), or the National Health Regulatory Agency, is Brazil’s powerful and independent regulatory body. Established in 1999, ANVISA is linked to the Ministry of Health and is responsible for the regulation and approval of not just pharmaceuticals, but also medical devices, food, and cosmetics.¹⁸ It is known for its rigorous, and often complex, evaluation processes.
Russia: Drug registration in Russia is primarily handled by the Ministry of Health (Minzdrav) of the Russian Federation, which issues the final marketing authorizations.²³ The
Federal Service for Surveillance in Healthcare (Roszdravnadzor) oversees inspections and post-market surveillance.²³ Crucially, Russia’s national system now operates within the harmonized framework of the
Eurasian Economic Union (EAEU), which aims to create a common pharmaceutical market with its member states.
India: The Central Drugs Standard Control Organisation (CDSCO) is India’s national regulatory body, operating under the Ministry of Health and Family Welfare.²⁶ It is headed by the
Drug Controller General of India (DCGI), who is responsible for the approval of new drugs and the regulation of clinical trials.²⁶ The CDSCO’s authority is shared with state-level drug control organizations, creating a complex federal regulatory structure.
China: The National Medical Products Administration (NMPA) is the regulatory authority for drugs, medical devices, and cosmetics in China.³⁰ Formerly known as the China Food and Drug Administration (CFDA), the NMPA has undergone a period of intense reform since 2015, dramatically overhauling its processes to align more closely with international standards while implementing unique, state-driven market access policies.³¹
South Africa: The South African Health Products Regulatory Authority (SAHPRA) is the national entity responsible for regulating all health products, including medicines, medical devices, and IVDs.³⁵ Established in 2018 to replace the former Medicines Control Council (MCC), SAHPRA has been focused on modernizing its processes, clearing a significant historical backlog of applications, and harmonizing its guidelines with international bodies like the European Medicines Agency (EMA).³⁷

Decoding the Dossier: CTD Adoption and National Deviations

The foundation of any drug application is the dossier—the comprehensive collection of technical, clinical, and administrative data. The global standard for this dossier is the Common Technical Document (CTD) format, developed by the International Council for Harmonisation (ICH). While all BRICS nations have moved towards adopting the CTD structure, the devil, as always, is in the details, particularly the country-specific requirements found in Module 1.

The CTD is structured into five modules:

Module 1: Administrative Information and Prescribing Information
Module 2: Common Technical Document Summaries
Module 3: Quality (Chemistry, Manufacturing, and Controls – CMC)
Module 4: Nonclinical Study Reports
Module 5: Clinical Study Reports

While Modules 2 through 5, which contain the core scientific data, are largely harmonized based on ICH standards, Module 1 is where national requirements diverge dramatically.²² This is the epicenter of regulatory complexity. It’s where you’ll find requirements for local language documentation, specific national application forms (like India’s ubiquitous Form 44), notarized and apostilled legal documents, and the mandatory appointment of a local authorized agent or representative.²⁶

Here’s a snapshot of the CTD landscape in each country:

Brazil utilizes an electronic CTD (eCTD) format. The dossier is broadly structured into two parts: an administrative section corresponding to Module 1, and the technical sections covering Modules 2-5.
Russia, as part of the EAEU, accepts the ICH-compliant CTD structure. However, Module 1 must contain all country-specific administrative documents and product labeling translated into Russian.²³
India accepts the CTD format for all submissions, which are now managed electronically through the national SUGAM Portal. The key administrative application is Form 44, which must accompany the dossier.⁴⁶
China has made the eCTD format mandatory for Abbreviated New Drug Application (ANDA) submissions, signaling its full alignment with global electronic submission standards.
South Africa also follows the CTD/eCTD format and has made significant strides in harmonizing its specific requirements with those of the EMA, making the process more familiar to companies with experience in Europe.³⁵

For a global generic company, the takeaway is clear. Your core scientific data package (Modules 3-5) can be largely standardized for submissions across these markets, creating significant efficiencies. However, the administrative and legal “wrapper” for that data—Module 1—requires a dedicated, country-specific approach. Underestimating the time, resources, and local expertise needed to compile a compliant Module 1 is one of the most common and costly mistakes a company can make, often leading to validation queries, application rejection, and significant delays in market entry.

Table 1: Comparative Regulatory and IP Landscape for Generic Drugs in BRICS Nations

To succeed in the BRICS markets, you need to think like a strategist, weighing the unique risk-reward profile of each country. The following table is designed to be the centerpiece of that strategic analysis. It provides a high-density, at-a-glance comparison of the most critical variables that influence your market entry decisions—from operational costs and R&D hurdles to legal risks and market timing. For an executive deciding where to allocate millions in R&D and filing fees, this table distills the complexities of five markets into a primary decision-making tool.

Parameter	Brazil	Russia (EAEU)	India	China	South Africa
Regulatory Body	ANVISA	Minzdrav / EAEU	CDSCO	NMPA	SAHPRA
Generic Application Name	Generic Drug Registration	Generic Drug Registration	Abbreviated New Drug Application (ANDA)	Abbreviated New Drug Application (ANDA)	Multisource/Generic Application
Dossier Format	eCTD (local variations)	EAEU CTD (Russian Module 1)	CTD (via SUGAM portal)	eCTD (Mandatory)	eCTD (EMA-aligned)
Bioequivalence Requirement	Required vs. local innovator at ANVISA-approved centers	Required; foreign studies acceptable	Required vs. Reference Listed Drug (RLD)	Required; must pass GQCE vs. innovator	Required; EMA-harmonized guidelines
Data Exclusivity	No ⁵⁴	Yes (6 years for reference drug)	No (consistently resisted in FTAs)	Yes (up to 6 years for new drugs) ³⁴	No
Patent Linkage System	No ⁵⁴	No (disconnected systems, but FAS acts post-approval)	No (confirmed by courts) ⁵⁹	Yes (US-style system with 9-month stay) ⁶²	No (depository patent system)
Est. Approval Timeline	12-24 months	6-8 months (EAEU target)	~9 months (stated goal, varies)	9-month stay for patent litigation	~17 months (new RBA process) ³⁹
Key Market Access Hurdle	Complex RDCs; mandatory local BE studies	EAEU harmonization; localization pressures	State/Central regulatory fragmentation; quality concerns	GQCE; VBP price pressure; Patent Linkage	Evolving SAHPRA guidelines; clearing historical backlog

Deep Dive: Brazil – Mastering ANVISA’s Complex Framework

Brazil represents one of the most tantalizing yet challenging markets in the BRICS bloc. As the largest healthcare market in Latin America, its potential is undeniable. However, its regulatory environment, governed by ANVISA, is notoriously complex and demanding. Success here requires meticulous preparation, a deep understanding of local requirements, and a robust legal strategy.

The Generic Drug Registration Pathway

The journey to market in Brazil begins and ends with ANVISA. Any foreign company wishing to register a drug must do so through a local office or a legally appointed agent or distributor. The entire process is managed electronically, with the dossier submitted in the eCTD format. A granted registration is valid for 10 years and can be renewed for successive periods.⁴⁴

While ANVISA has made efforts to streamline its processes, manufacturers should be prepared for a lengthy review. The average analysis time for a drug registration can range from 12 to 24 months, depending on the complexity of the product and the quality of the submitted dossier. The process involves several distinct stages with their own timelines, including an initial 60-day period for the first evaluation by ANVISA, followed by up to 120 days for the company to respond to any queries or deficiencies identified.

The Crux of the Matter: Bioequivalence and Biowaivers

For any generic drug in Brazil, the scientific cornerstone of the application is the demonstration of therapeutic equivalence to the innovator product. This is primarily established through bioequivalence (BE) studies.⁵⁵ However, ANVISA imposes a critical and often challenging local requirement: BE studies must be conducted using the specific innovator product that is registered and marketed in Brazil (the “reference drug”) as the comparator. Furthermore, these studies must be carried out at clinical research centers that have been inspected and certified by ANVISA. This precludes the use of BE data generated against, for example, a European or US reference product, adding a significant layer of cost and logistical complexity to the development program for Brazil.

Recognizing that a full in-vivo BE study is not always scientifically necessary, ANVISA has established a framework for biowaivers, which allow companies to use in-vitro data (like comparative dissolution studies) to justify the exemption of a BE study. This framework is governed by a series of specific regulations known as Resolutions of the Collegiate Board (RDCs). A key regulation is RDC 749/2022, which updated the criteria for granting biowaivers. The primary goal of this RDC is to ensure the interchangeability of generic medicines with their reference products while speeding up the approval process for lower-risk products, such as additional strengths of a product that has already demonstrated bioequivalence at another strength.

Navigating these RDCs is essential. Other critical regulations that shape the lifecycle of a generic product in Brazil include RDC 47/2009, which governs the harmonization of medication leaflets to ensure consistency between the generic and reference product, and RDC 73/2016, which outlines the complex requirements for filing post-approval changes.⁷¹

The IP Landscape: A Haven for “At-Risk” Launches

Brazil’s approach to intellectual property is fundamentally different from that of the United States or China, and this difference creates a unique strategic landscape for generic manufacturers. The system is explicitly designed to prioritize public health and access to medicines over the extension of monopoly rights.

This philosophy is enshrined in two key policies: the absence of data exclusivity and the absence of patent linkage.

No Data Exclusivity: Brazil does not grant data exclusivity for medicines intended for human use.⁵⁴ This means that ANVISA is legally permitted to rely on the safety and efficacy data submitted by the innovator company to approve a subsequent generic application. The generic manufacturer only needs to prove pharmaceutical equivalence and bioequivalence; they are not required to repeat the costly and time-consuming preclinical and clinical trials already conducted for the reference drug. This is a cornerstone of Brazil’s pro-access policy, designed to facilitate the rapid entry of affordable generics upon patent expiry.
No Patent Linkage: There is no formal “patent linkage” system connecting ANVISA’s drug approval process with the patent system managed by the Brazilian Patent and Trademark Office (INPI). ANVISA’s mandate is to assess a drug’s quality, safety, and efficacy. It does not, and legally cannot, refuse to grant marketing authorization for a generic drug on the grounds that it may infringe an existing patent.

The combined effect of these two policies creates a high-risk, high-reward environment that is particularly conducive to “at-risk” launches. The primary barrier to market entry in Brazil is purely regulatory. A generic company can, and often does, secure full marketing authorization from ANVISA while the innovator’s patents are still in force. This shifts the entire strategic calculation. The key question for a generic company is not, “Can we get past the patent gatekeeper at the regulatory agency?” but rather, “Are we confident enough in our non-infringement or patent invalidity position to launch our product and face the inevitable, and often aggressive, patent infringement lawsuit from the innovator?”

This dynamic shifts the entire risk profile of a Brazilian market entry. It favors companies with sophisticated legal teams, a high tolerance for risk, and the financial resources to withstand protracted litigation. It allows a generic company to use its regulatory approval as a powerful lever to put commercial pressure on patent holders, potentially forcing a favorable settlement or license agreement. Consequently, Brazil is a prime market for challenging weaker secondary patents (e.g., for new formulations or methods of use) and for launching generics of products where the core compound patent has already expired.

Deep Dive: Russia & the EAEU – Harmonization, Localization, and Market Access

The Russian pharmaceutical market is a formidable paradox: a market demonstrating robust growth in local currency, yet one profoundly shaped by geopolitical pressures and a state-led campaign for technological sovereignty. Navigating this landscape requires understanding not just Russia’s national regulations, but its central role within the broader Eurasian Economic Union (EAEU). Success in Russia is a game of deep localization, strategic partnerships, and a mastery of the new, harmonized EAEU framework.

Navigating the Eurasian Economic Union (EAEU) Framework

Since January 2021, the drug registration process in Russia has been mandatorily governed by the unified rules of the EAEU, a trading bloc that also includes Belarus, Kazakhstan, Armenia, and Kyrgyzstan.²³ This transformative shift aims to create a common pharmaceutical market of over 180 million people, replacing disparate national procedures with a single, harmonized system. All medicines that were registered under old national procedures must be brought into compliance with EAEU requirements by the end of 2025.

Within Russia, the Ministry of Health (Minzdrav) remains the competent authority that issues the final marketing authorizations, while Roszdravnadzor is responsible for GMP inspections and post-market surveillance.²³

The EAEU framework provides two primary pathways for drug registration ⁴⁵:

Mutual Recognition Procedure (MRP): This is a sequential process. You first submit your full dossier and obtain registration in a single “reference state” of your choosing within the EAEU. Once approved there, you can apply for recognition of that approval in the other member states (the “concerned member states”). This second stage is significantly faster, allowing for a phased market entry.
Decentralized Procedure (DCP): This procedure allows for the parallel submission of a registration application in several or all EAEU member states simultaneously. You still select a reference state to lead the evaluation, but the other chosen states participate in the review process from the beginning.

The EAEU has set an ambitious target review timeline of 210 calendar days for the initial registration in a reference state, though this does not include “clock stops” where the regulator pauses the review to await responses from the applicant. The official application fees in Russia are relatively modest, typically ranging from $5,000 to $10,000 USD. However, companies should budget for additional costs related to dossier preparation, translation, and local agent fees.

Dossier and Clinical Requirements

The EAEU has adopted the internationally recognized CTD format for its registration dossiers, bringing its requirements more in line with global standards.²³ However, there are critical localization requirements.

Dossier Language: Module 1, which contains all administrative information, application forms, and product labeling (Summary of Product Characteristics, Patient Information Leaflet, and packaging mock-ups), must be provided in Russian. This is a non-negotiable requirement and necessitates expert translation services. A significant advantage of the EAEU system is that the voluminous scientific data in Modules 2 through 5 can often be submitted in English, although key summaries and sections within Module 3 (Quality/CMC) may also require translation.⁴⁵
Clinical Data: For generic drugs, the EAEU framework offers a major strategic benefit: bioequivalence studies conducted outside of the EAEU are generally accepted. This means you can leverage BE data from studies conducted in Europe or elsewhere, avoiding the cost and time of repeating these studies specifically for the Russian market. However, be prepared for regulators to potentially request that your clinical summary includes region-specific epidemiological data to demonstrate the relevance of the drug to the local population.

The IP Landscape: A Disconnected System with Emerging Teeth

Russia’s intellectual property system for pharmaceuticals is unique and presents a complex set of risks. Unlike in the US or China, the country has two relatively autonomous and disconnected legal frameworks: the state registration of medicines, governed by the Federal Law “On Circulation of Medicines,” and the patent protection of inventions, governed by the Civil Code.

No Patent Linkage: Crucially, there is no formal patent linkage system in Russia. When you submit a generic drug application, the Ministry of Health will review it for quality, safety, and efficacy only. It does not conduct any checks to determine if your product infringes on existing patents. This means it is entirely possible to receive full marketing authorization for a generic drug while the innovator’s patent is still valid.
Data Exclusivity: In a move to harmonize with international standards and incentivize innovators, the EAEU framework does provide for a period of data exclusivity. The results of preclinical and clinical trials for an original (innovator) medicine are protected for 6 years from the date of its registration in the reference state. During this period, a generic applicant cannot obtain registration by referencing the innovator’s protected data.

This “no-linkage” system might suggest that Russia is a straightforward market for “at-risk” launches. However, this assumption would be a grave miscalculation. While the Minzdrav will not block your approval based on patents, another powerful government body acts as a de facto, post-approval enforcement mechanism: the Federal Antimonopoly Service (FAS).

The recent and widely publicized case involving AstraZeneca’s cancer drug osimertinib provides a critical lesson. A Russian company, Axelpharm, obtained marketing authorization for a generic version of the drug and began participating in state procurement tenders. AstraZeneca did not sue for patent infringement in the traditional sense; instead, it filed a complaint with the FAS, alleging that Axelpharm was engaging in “unfair competition” by selling a product that was still under patent protection. The FAS agreed, launching an investigation that resulted in a substantial fine for Axelpharm and an order to cease selling the generic product.

This case demonstrates that while there is no pre-approval patent linkage at the Ministry of Health, there is a very real and potent post-approval enforcement risk via the FAS. The strategic challenge in Russia, therefore, is not simply passing the regulatory gate, but surviving the immediate post-launch legal and administrative assault. A successful launch strategy for Russia must include a pre-emptive defense plan for a potential FAS investigation, complete with robust non-infringement and invalidity arguments. This transforms Russia from a simple “no-linkage” market into a complex “hybrid-risk” environment where regulatory approval and commercial viability are two distinct and formidable hurdles. As one executive aptly put it, success requires a “delicate balancing act between maintaining market access… and mitigating geopolitical risk”.

Deep Dive: India – Capitalizing on the “Pharmacy of the World”

India holds a unique and powerful position in the global pharmaceutical ecosystem. Known as the “pharmacy of the world,” it is a behemoth of generic drug manufacturing, accounting for approximately 20% of the global supply by volume and 40% of the generic demand in the United States. For any generic company with global ambitions, a presence in India is not optional; it is essential. However, capitalizing on this market requires navigating a regulatory system that is as fragmented and challenging as it is full of opportunity.

The ANDA-Equivalent Process under CDSCO

The approval process for generic drugs in India is overseen by the Central Drugs Standard Control Organisation (CDSCO) and is broadly analogous to the Abbreviated New Drug Application (ANDA) process in the United States. The entire submission process is now digitized and managed through the online SUGAM Portal.⁴⁶ The central document for any application to import or manufacture a new drug (which includes generics new to the Indian market) is

Form 44.⁴⁶ This form, submitted with a full CTD dossier, details everything from the drug’s composition and patent status to the preclinical and clinical data supporting its approval.⁴⁷

However, the Indian regulatory system is notoriously complex due to its federal structure. Power is divided between the central CDSCO, which handles the approval of “new drugs,” and the various state-level drug regulatory authorities, which are responsible for granting manufacturing licenses and overseeing routine quality control. This division has been criticized for creating inconsistencies, a lack of transparency, and opportunities for “forum shopping,” where a manufacturer might seek a license in a state with more lenient oversight.

Experts have been vocal about the system’s shortcomings, pointing to “massive failures” that include chronic understaffing, inadequate drug testing infrastructure, and the shocking absence of a mandatory, legally enforceable drug recall mechanism. A senior CDSCO official candidly admitted the limitations of their public data, stating, “The data we do publish is merely a drop in the vast ocean”. This sentiment was echoed by a former Drugs Controller General, who admitted in an interview that if stringent US standards were applied to Indian facilities, “almost all drug facilities” would have to be shut down.

Bioequivalence and Quality Concerns

To gain approval, a generic applicant must submit data from bioequivalence (BE) studies demonstrating that their product is therapeutically equivalent to the designated Reference Listed Drug (RLD). This is a standard global requirement.

Despite India’s status as a manufacturing giant, persistent concerns about the quality of some domestically produced generics remain a significant issue. A senior CDSCO official has noted that Micro, Small & Medium Enterprises (MSMEs) are particularly “notorious for producing substandard generic medicines in India,” often lacking effective quality management systems and failing to comply with Good Manufacturing Practices (GMP). These concerns are not just anecdotal. A recent academic study found a troubling correlation, linking generic drugs manufactured in India to a significantly higher number of “severe adverse events” reported to the US FDA compared to equivalent drugs produced in the United States.

The IP Landscape: Pro-Generic and Anti-Linkage

India’s intellectual property framework is arguably the most pro-generic among the BRICS nations, a deliberate policy choice designed to foster a robust domestic industry and ensure broad access to affordable medicines.

No Patent Linkage: India has a clear and legally affirmed separation between its drug regulatory and patent systems. The Drugs and Cosmetics Act and the Patents Act operate independently, and Indian courts have repeatedly rejected attempts by innovator companies to establish a link between the two.⁵⁹ The DCGI’s mandate is to evaluate a drug’s safety and efficacy for the Indian population; it is not a patent enforcement agency.
No Data Exclusivity: India has been a staunch opponent of data exclusivity provisions in international trade negotiations. The country has consistently and successfully resisted pressure from trading partners, including the UK and the European Free Trade Association (EFTA), to introduce data exclusivity, viewing it as a “TRIPS-plus” measure that would unnecessarily delay the entry of affordable generics.

This combination of regulatory challenges and a favorable IP environment creates a unique strategic dynamic. The weaknesses in India’s regulatory system—its fragmentation, under-resourcing, and quality control gaps—represent a double-edged sword for manufacturers. On one hand, the staunchly pro-generic IP stance and relatively lower regulatory hurdles (compared to a market like China) create an environment with low barriers to entry. It is easier and faster to get a product to market in India.

On the other hand, the very same quality concerns that plague the system create a powerful opportunity for differentiation. In a market where consumers and healthcare professionals are increasingly aware of and concerned about the quality of generic medicines, a company that can build its brand on a platform of unimpeachable quality stands to gain a significant competitive advantage. The strategic play in India is therefore twofold: first, leverage the favorable IP environment for rapid market entry. Second, simultaneously invest in and aggressively market a message of superior quality. A company that can clearly demonstrate that its products are manufactured to the highest international standards—for instance, by highlighting its approvals from stringent authorities like the USFDA or EMA—can command trust and loyalty. In a system where the baseline is often perceived as unreliable, this “flight to quality” can be the most potent market access strategy of all.

Deep Dive: China – Quality, Procurement, and the Patent Linkage Revolution

No pharmaceutical market in the world has undergone a more dramatic and rapid transformation than China’s. In less than a decade, it has evolved from a landscape characterized by long review times and inconsistent quality into a highly sophisticated, intensely competitive arena governed by a trio of powerful, interconnected reforms. For generic manufacturers, the message from Beijing is clear: the old rules no longer apply. Success in modern China requires a mastery of quality, an ability to compete on price at massive scale, and the legal acumen to navigate a new, US-style patent enforcement system.

The NMPA’s Triple Revolution: GQCE, VBP, and Patent Linkage

Since 2015, the National Medical Products Administration (NMPA) has systematically overhauled the country’s drug regulatory and market access environment. This effort has been driven by three landmark policies that work in concert to reshape the industry.

Generic Quality Consistency Evaluation (GQCE): This is perhaps the most fundamental reform. The GQCE is a mandatory re-evaluation program that requires generic drugs to prove they are equivalent in both quality and clinical efficacy to the original innovator drug.¹⁵ This is a far higher standard than was previously required and has forced a massive, industry-wide investment in R&D and process upgrades. The technical requirements are stringent, covering everything from formulation and stability to the quality of active pharmaceutical ingredients (APIs), excipients, and even primary packaging materials. The GQCE has effectively acted as a quality filter, raising the bar for market entry and eliminating many smaller, lower-quality players who could not meet the new standards.
Volume-Based Procurement (VBP): Once a generic drug has passed the GQCE, it often becomes eligible to participate in the VBP program. VBP is a national centralized procurement system where pharmaceutical companies submit bids for massive, province-spanning contracts to supply public hospitals. The prize is guaranteed volume, but the price is steep. Winning bids often involve dramatic price cuts, with discounts of 50% to 90% compared to previous prices being common. This policy has created immense price pressure across the market, fundamentally altering the profitability of many generic products.
Patent Linkage System: The third pillar of reform is a completely new intellectual property enforcement mechanism, which we will explore in detail below.

The IP Landscape: A New Era of Patent Enforcement

In a landmark move that brought its system much closer to that of the United States, China implemented a full-fledged patent linkage system, effective July 2021.⁴³ This system directly connects the NMPA’s drug approval process with the patent status of the innovator drug. The key features include:

A Chinese “Orange Book”: The NMPA has established the China Patent Information Registration Platform for Marketed Drugs (CPIRPMD), where innovator companies must list relevant patents covering their approved drugs.⁶³
Generic Applicant Declarations: When submitting an ANDA, a generic manufacturer must make one of four types of declarations for each patent listed on the platform, similar to the Paragraph I-IV certifications in the US. A Type IV declaration asserts that the innovator’s patent is invalid or will not be infringed by the generic product.⁶²
Automatic Stay on Approval: A Type IV declaration is a trigger. The generic applicant must notify the patent holder, who then has a 45-day window to file a lawsuit or an administrative complaint. If a suit is filed, the NMPA imposes an automatic 9-month stay on the approval of the generic drug, allowing time for the patent dispute to be resolved in court or by the China National Intellectual Property Administration (CNIPA).⁶²
Market Exclusivity for “First Generic”: To incentivize patent challenges, the system grants a 12-month period of market exclusivity to the first generic applicant that successfully challenges an innovator’s patent and obtains marketing approval.⁶³

In addition to this new linkage system, China also provides up to 6 years of regulatory data protection for innovative new drugs, preventing other companies from relying on the innovator’s clinical trial data to support their own applications during that period.³⁴

These three major reforms—GQCE, VBP, and Patent Linkage—should not be viewed as separate policies. They are a brilliantly coordinated industrial strategy designed to achieve multiple state objectives simultaneously. First, the GQCE acts as a quality filter, weeding out substandard products and forcing the entire domestic industry to upgrade its capabilities. Second, the VBP program leverages the state’s immense purchasing power to force the remaining high-quality players into a brutal price competition, ensuring that the public healthcare system receives top-tier drugs at the lowest possible prices. Finally, the robust new IP protections offered by the patent linkage system and data exclusivity serve as the crucial incentive for global innovator companies to bring their newest and most advanced medicines to the Chinese market in the first place, creating the future pipeline of reference drugs that will feed this entire system.

The result of this coordinated strategy is the creation of a “winner-take-all” market. This is no longer an emerging market in the traditional sense; it is a hyper-competitive, high-stakes arena that rewards only the most sophisticated players. To win in China, a generic company must possess the R&D prowess to pass the demanding GQCE, the manufacturing scale and cost efficiency to survive a VBP tender at a razor-thin margin, and the legal and strategic sophistication to successfully navigate the new patent linkage labyrinth.

Deep Dive: South Africa – A Modernizing Gateway to Africa

South Africa stands as a critical and evolving market within the BRICS constellation. As one of the most advanced nations on the African continent, it serves not only as a significant market in its own right but also as a strategic gateway to the broader sub-Saharan region. The country’s regulatory landscape has been in a state of dynamic transformation, with the South African Health Products Regulatory Authority (SAHPRA) working to overcome historical challenges and align its framework with global best practices.

Navigating the SAHPRA Framework

The primary regulatory body in South Africa is SAHPRA, which was established in 2018 to replace the old and often slow Medicines Control Council (MCC).³⁵ A key mandate for the new authority has been to accelerate the drug registration process and, critically, to clear a massive historical backlog of applications that had languished for years under the old system.

SAHPRA has made significant progress on this front. Through the implementation of new review pathways, including a risk-based assessment (RBA) process, the authority has dramatically reduced approval timelines. A 2023 study assessing SAHPRA’s performance found that the median approval time for a generic medicine under the old MCC process was a staggering 2,092 calendar days. The new RBA process has cut this down to a median of 511 days—still a lengthy period, but a monumental improvement.³⁹

Applications for generic medicines (referred to as “multisource” products) are submitted to SAHPRA in the standard CTD or eCTD format, making the technical dossier requirements familiar to any company operating globally.

Bioequivalence and Harmonization with International Standards

Demonstrating therapeutic equivalence through bioequivalence (BE) studies is a core requirement for generic approval in South Africa. What makes South Africa particularly attractive from a regulatory strategy perspective is SAHPRA’s explicit policy of harmonization with leading international regulatory bodies.

The authority’s primary Quality and Bioequivalence guideline (SAHPGL-PEM-02) clearly states that SAHPRA has decided to align its policies and procedures with those of the European Medicines Agency (EMA), endorsing the principles contained in the EMA’s guidelines.⁵¹ This means that for many technical and clinical requirements, the standards expected by SAHPRA are the same as those in the European Union. This harmonization extends to the use of reference products; applicants can often use innovator products sourced from other recognized regulatory authority (RRA) jurisdictions, such as the EU or the US, for their comparative studies, provided proper justification is given.

This policy of harmonization has led to the creation of “reliance pathways.” A generic drug that has already been approved by a recognized authority like the EMA can potentially undergo an “abridged” or “verified” review process at SAHPRA, which is significantly faster and less burdensome than a full, de novo review.

The IP Landscape: A System in Transition

South Africa’s intellectual property system for pharmaceuticals is unique and has been a subject of intense debate and reform efforts.

A Depository Patent System: Historically, South Africa has operated a depository or non-examining patent system. This means that patents have been granted based on compliance with administrative formalities, without a rigorous, substantive examination of the invention’s novelty, inventive step, or utility.⁶⁴ This has led to criticism that the country grants an unacceptably high number of patents, including many “weak” secondary patents that might not withstand scrutiny in other jurisdictions.
No Patent Linkage or Data Exclusivity: In line with its strong public health focus, South Africa does not have a formal patent linkage system or data exclusivity provisions. The government has actively pursued policies to improve access to affordable medicines, including allowing for parallel importation (importing a patented drug from another country where it is sold more cheaply) and promoting generic substitution.⁸³
The “Patent Declaration”: A noteworthy development is the inclusion of a specific section for a “Patent Declaration” (m1-2-4-patent-declaration) in South Africa’s eCTD specifications.⁸⁶ While the available documentation does not fully detail the legal weight or specific requirements of this declaration, its formal inclusion in the dossier structure suggests a potential move towards a more structured consideration of patent status during the regulatory process, even if it falls short of a full linkage system. This is a critical area for manufacturers to monitor closely.

SAHPRA’s modernization and its embrace of international harmonization create a powerful strategic opportunity. The explicit policy of aligning with the EMA and establishing reliance pathways is a game-changer for global generic companies. This means that a South African submission no longer needs to be a completely standalone effort. A successful marketing authorization application submitted to the EMA can be directly leveraged to accelerate the SAHPRA approval process, significantly reducing both the time and cost of market entry.

This positions South Africa as an ideal “fast-follower” market. For products that a company is already developing and launching in Europe, the incremental effort to file in South Africa is substantially reduced. This regulatory efficiency, combined with its status as a key commercial hub, makes South Africa an attractive and logical gateway for expanding a product’s reach into the broader African continent.

Crafting a Winning BRICS Strategy: Turning Intelligence into Advantage

Having dissected the individual regulatory and IP landscapes of the five BRICS nations, it becomes clear that a monolithic, one-size-fits-all strategy is a recipe for failure. The path to success lies in a nuanced, sequenced, and data-driven approach that treats each market as a distinct strategic challenge. This requires integrating regulatory intelligence, legal analysis, and commercial objectives into a single, cohesive plan.

Strategic Portfolio Selection and Market Sequencing

The temptation to pursue a simultaneous “BRICS launch” for a new generic product should be resisted. A far more effective approach is to sequence your market entries based on the specific risk-reward profile presented by each country’s IP environment and regulatory hurdles.

A logical strategic sequence could look like this:

Prioritize “At-Risk” Friendly Markets: For products where you have a strong non-infringement argument but the innovator’s patents are still in force, prioritize initial launches in the markets that lack patent linkage: India, Brazil, and South Africa. Securing early marketing authorization and launching “at-risk” in these jurisdictions allows you to start generating revenue, build market presence, and put commercial pressure on the patent holder, potentially leading to favorable global settlements.
Tackle the “Litigation-First” Market: For high-value products where you have a robust case for patent invalidity and the resources for litigation, China should be a primary target. Its new patent linkage system is a high-stakes arena, but a successful patent challenge is rewarded with a valuable 12-month period of market exclusivity against other generics.⁶³ This makes China a market where an aggressive legal strategy can yield a significant commercial payoff.
Address the “Hybrid-Risk” Market: Russia should be approached with a carefully coordinated dual strategy. While you can secure regulatory approval from the Minzdrav without patent linkage, you must be fully prepared for an immediate post-launch challenge from the innovator via the Federal Antimonopoly Service (FAS).⁶⁰ This requires having your “unfair competition” defense strategy ready to deploy the moment your product hits the market.

This sequenced approach allows you to tailor your resource allocation and risk exposure, using early wins in more accessible markets to fund the more complex and costly battles in jurisdictions like China.

The Power of Patent Intelligence: Leveraging DrugPatentWatch

In this complex global chess match, timely and accurate intelligence is your most valuable asset. A regulatory approval is worthless if you are immediately blocked by an unforeseen patent. This is where a sophisticated competitive intelligence platform like DrugPatentWatch becomes an indispensable strategic tool, transforming raw patent data into actionable market insights.

Here’s how you can integrate such a platform into your strategic workflow:

Opportunity Identification: The foundation of any generic portfolio is identifying the right targets. Use comprehensive patent expiry data to map out the most lucrative opportunities emerging from the upcoming patent cliff.¹² Platforms like
DrugPatentWatch provide curated databases of drug patents and projected generic entry dates, allowing you to focus your R&D resources on the products with the highest commercial potential.
Freedom-to-Operate (FTO) Analysis: Before committing millions of dollars to development and bioequivalence studies, a rigorous FTO analysis is non-negotiable. This deep dive into the patent landscape identifies any third-party patents that could block your product’s launch, covering not just the active ingredient but also formulations, methods of use, and manufacturing processes.¹² FTO is your primary risk mitigation tool, preventing you from investing heavily in a product you can never legally sell.
Litigation Intelligence: The outcome of patent litigation in one country can provide powerful clues about the strength or weakness of a patent in another. By tracking ongoing patent challenges, such as Paragraph IV litigation in the United States, you can gain valuable insights into a brand’s patent portfolio.⁸⁸
DrugPatentWatch offers detailed information on patent litigation, helping you assess the defensibility of an innovator’s patents and identify potential vulnerabilities to exploit in your own legal strategy.
First-to-File Strategy: The data is unequivocal: the first generic to launch enjoys a significant and lasting first-mover advantage, often capturing a dominant market share that later entrants struggle to erode.⁹² Winning this race to market requires precision timing. Using real-time intelligence on patent statuses, litigation outcomes, and regulatory timelines from a platform like
DrugPatentWatch can help you pinpoint the earliest possible filing and launch windows with unparalleled accuracy.

Beyond the Dossier: Navigating Local Market Dynamics

Securing regulatory approval is a critical milestone, but it is only half the battle. A marketing authorization is worthless if your product cannot gain meaningful market access. Your strategy must extend beyond the regulatory affairs department to encompass the unique commercial realities of each BRICS nation.

Pricing and Procurement: Be prepared for intense pricing pressure. In China, success is increasingly dictated by your ability to win a Volume-Based Procurement (VBP) tender, which requires aggressive pricing and massive scale. In Russia, a significant portion of the market is driven by state procurement, which has strong preferences for locally manufactured products. Understanding these mechanisms is key to building a viable commercial model.
Localization is Non-Negotiable: Success in the BRICS markets requires a local footprint. This goes beyond simply hiring a local agent. It means producing documentation in local languages, such as Russian for an EAEU filing. It may mean establishing local manufacturing or packaging partnerships to comply with government policies that favor domestic production, a key element of Russia’s “Pharma 2030” strategy and a growing trend in China.
The Integrated Approach: The most critical strategic takeaway is that regulatory affairs, legal/IP, manufacturing, and commercial strategy cannot operate in silos. A successful BRICS market entry requires constant, dynamic integration across these functions. The decision to file in China (a regulatory action) is entirely dependent on the legal team’s assessment of the patent linkage risk. The ability to compete in a VBP tender in China (a commercial action) is dictated by the manufacturing team’s ability to produce at an incredibly low cost per unit. The choice of a reference product for a bioequivalence study in Brazil (an R&D action) has profound regulatory and commercial consequences.

The winning strategy is not a linear, sequential process but a continuous, iterative loop where intelligence from each function informs the others in real-time. Companies that structure their BRICS market-entry teams to be cross-functional from day one will be the ones who can effectively navigate the multifaceted challenges and capitalize on the immense opportunities these dynamic markets present.

Conclusion: A New Era of Strategic Generic Development

The rise of the BRICS nations represents a fundamental and irreversible shift in the global pharmaceutical landscape. For generic drug manufacturers, these markets are no longer a secondary consideration but the primary engine of future growth. Yet, as we have seen, this opportunity is wrapped in layers of complexity. Brazil, Russia, India, China, and South Africa are not a monolithic bloc but five distinct ecosystems, each with a unique regulatory philosophy, intellectual property regime, and set of market access challenges.

The era of simple replication and competing solely on price is over. Success in this new environment demands a new level of strategic sophistication. It requires:

Deep Regulatory Acumen: A granular understanding of the nuanced filing requirements, from the specifics of Brazil’s RDCs and India’s Form 44 to the harmonized procedures of the EAEU.
Sophisticated Legal Strategy: The ability to navigate diverse IP landscapes, from the “at-risk” launch environment of Brazil to the complex, litigation-driven patent linkage system of China.
Commitment to Quality: Meeting the rising quality standards, exemplified by China’s GQCE, is no longer optional but a prerequisite for market entry and a key differentiator in markets like India.
Operational Excellence: The manufacturing scale and cost efficiency to compete in price-sensitive, high-volume procurement systems like China’s VBP.
An Integrated, Data-Driven Approach: The agility to synthesize regulatory, legal, and commercial intelligence into a cohesive, cross-functional strategy, leveraging powerful tools to turn patent data into a decisive competitive advantage.

The path forward is challenging, but the rewards for those who master this new landscape are immense. The companies that thrive will be those that move beyond a tactical, country-by-country approach and adopt a truly global, integrated strategy. They will be the ones who see the regulatory maze not as an obstacle, but as an opportunity to outmaneuver the competition. The BRICS imperative is here, and it will define the next generation of leaders in the generic pharmaceutical industry.

Key Takeaways

BRICS are Not a Monolith: Each of the five nations (Brazil, Russia, India, China, South Africa) has a unique regulatory, IP, and market access environment requiring a tailored entry strategy. A “one-size-fits-all” approach will fail.
Quality is the New Barrier to Entry: Rising quality standards, most notably China’s Generic Quality Consistency Evaluation (GQCE), are replacing price as the primary competitive differentiator. Success now requires investment in high-quality R&D and manufacturing.
Patent Linkage is a Decisive Factor: The presence or absence of a patent linkage system is a critical strategic variable. China’s US-style system creates a litigation-driven market, while the lack of linkage in Brazil, India, and South Africa creates opportunities for “at-risk” launches. Russia presents a hybrid risk with its post-approval enforcement via the Federal Antimonopoly Service (FAS).
Harmonization Creates Efficiency: SAHPRA’s alignment with EMA guidelines and Russia’s integration into the EAEU framework create significant strategic efficiencies. A successful filing in a major market (like the EU) can be leveraged to accelerate approval in these “fast-follower” jurisdictions.
Intelligence is the Ultimate Advantage: In a landscape defined by patent cliffs and complex regulations, the ability to transform patent and market data into actionable intelligence is paramount. Leveraging platforms like DrugPatentWatch for opportunity identification, FTO analysis, and litigation tracking is essential for making informed, strategic decisions.
Integration is Key to Execution: The most successful companies will be those that break down internal silos and foster a cross-functional approach, integrating regulatory, legal, R&D, and commercial strategies from the earliest stages of portfolio planning.

Frequently Asked Questions (FAQ)

1. Which BRICS market offers the quickest path to market for a generic drug?

There is no single “quickest” path, as it depends heavily on the product’s specific patent situation. For a drug with no patent barriers, Russia’s EAEU process has a target timeline of 6-8 months , and India’s CDSCO has a stated goal of around 9 months. However, for a drug with existing patents, India and Brazil may offer a faster path to regulatory approval due to the absence of patent linkage, but this comes with the high risk of post-launch litigation. China’s 9-month litigation stay makes its timeline for a contested drug predictable but not necessarily fast.

2. How has China’s Volume-Based Procurement (VBP) program changed the strategic calculation for generic manufacturers?

VBP has fundamentally changed the game from a margin-based to a volume-based model. It creates a “winner-take-all” dynamic where winning a tender guarantees massive market share but at extremely low prices, often with discounts exceeding 90%. This forces companies to have an exceptionally low cost of goods and large-scale manufacturing capacity. Strategically, it means companies must decide if they can compete on this scale or if they should focus on niche products that are less likely to be included in VBP tenders. It also elevates the importance of passing the GQCE, which is often a prerequisite to even bid.

3. Is it possible to use bioequivalence (BE) data from a study conducted in Europe or the US for all BRICS submissions?

Not for all. Russia’s EAEU framework is the most flexible, generally accepting foreign BE data. South Africa, through its harmonization with the EMA, also offers pathways for reliance on data from recognized regulatory authorities. However, Brazil is the strictest, typically requiring that BE studies be conducted in-country at ANVISA-certified centers against the locally sourced Brazilian reference product. China’s GQCE also requires comparison against the designated innovator reference drug, which may necessitate new studies. India requires comparison against the Indian Reference Listed Drug. Therefore, a global BE study strategy must be carefully planned to accommodate these divergent requirements.

4. What is the most significant non-regulatory barrier to success in the BRICS markets?

Beyond the formal filing requirements, the most significant barrier is often navigating the local market access and commercial environment. This includes dealing with powerful state-run procurement systems (like in China and Russia), complex and fragmented distribution channels, and intense price pressure. Furthermore, the push for “localization” in countries like Russia and China—favoring domestic manufacturers through procurement preferences and other policies—can be a major hurdle for foreign companies without a local manufacturing partner or presence.9

5. How should a generic company approach a product with multiple “secondary” patents (e.g., for formulation, method of use) in the BRICS nations?

This requires a highly nuanced, country-by-country legal assessment. In South Africa, where the patent system is historically a depository one, these secondary patents may be weaker and more susceptible to challenge. In India, Section 3(d) of the Patents Act creates a high bar for patenting minor modifications, making many secondary patents vulnerable. In Brazil, the lack of patent linkage makes launching at-risk against weaker secondary patents a viable, albeit aggressive, strategy. Conversely, in China’s new patent linkage system, these secondary patents must be listed in their “Orange Book” and challenged directly, triggering a 9-month stay and potential litigation. A successful strategy involves using patent intelligence to assess the strength of these secondary patents and prioritizing markets where the legal framework is most favorable for a challenge.